Teva Pharmaceutical (TEVA) Misses Q4 EPS by 1c

Teva Pharmaceutical (NYSE: TEVA) reported Q4 EPS of $1.32, $0.01 worse than the analyst estimate of $1.33. Revenue for the quarter came in at $5.2 billion versus the consensus estimate of $5.26 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tractor Supply (TSCO) Tops Q1 EPS by 12c ; Offers Guidance
• Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
• Netlist (NLST) Misses Q1 EPS by 1c